uniQure (QURE) CEO Matthew Kapusta Sells $2.1M of Stock
Matthew Kapusta, CEO of uniQure N.V., sold 41,671 shares valued at approximately $2.08 million on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Matthew Kapusta, CEO, Managing Director at uniQure N.V. ($QURE), sold 41,671 shares at an average price of $50, worth about $2.08 million, on June 18, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $QURE is up 6.1% after 1 week, down 14.2% after 1 month and down 53.0% to date (from the $46.29 close on Jun 18, 2026).
QURE
uniQure N.V.
Key Points
- Matthew Kapusta sold 41,671 shares of uniQure N.V. for about $2,083,550 on June 18, 2026.
- uniQure's stock is currently trading around $45.77, which is significantly above its 52-week low of $8.73.
- Analysts have a consensus rating of 'strong buy' for uniQure, with a mean target price of $61.46.
Get $QURE trade alerts by text
We text you when insiders, Congress or big funds trade $QURE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated uniQure N.V. alert may contain errors. Disclosures
CEO's Recent Sale
Matthew Kapusta, the CEO and Managing Director of uniQure N.V. (NasdaqGS: QURE), sold 41,671 shares on June 18, 2026, for about $2,083,550. This sale comes as part of a planned strategy and reflects his ongoing management of his holdings in the company.
Kapusta's Trading History
This sale is not the first for Kapusta this month. Just a day earlier, on June 17, he sold 164,429 shares for approximately $7.29 million. He also made a purchase of 4,128 shares on June 24 for $130,898.88. These transactions indicate active management of his position in the company, which may suggest confidence in uniQure's future prospects despite the recent sales.
Institutional Activity
No other funds have recently reported changes in their positions regarding uniQure N.V., so there’s no additional institutional activity to highlight at this time.
How uniQure N.V. Stock Has Traded
uniQure's stock is currently trading at around $45.77. This price is well above its 52-week low of $8.73 and reflects a significant rebound over the past year. The shares are also above the 50-day moving average of $40.20, indicating positive momentum.
Recent Earnings
For the quarter ended March 31, 2026, uniQure reported revenues of about $18.67 million, showing a growth of 11% compared to the previous year. However, the company continues to operate at a loss with an EPS of -$4.03. The next earnings report is expected on November 9, 2026, which could provide further insights into the company's financial health.
Insider Buying and Selling at uniQure N.V.
In addition to Kapusta's recent sale, Chief Medical Officer Walid Abi-Saab sold 1,434 shares on June 26, 2026, for about $67,197.24. This activity among insiders shows a mix of buying and selling, which can be common as executives manage their personal finances and investment strategies.
Analysts Set New Price Targets
Analysts have recently been active in adjusting their ratings for uniQure. On October 5, 2026, Barclays downgraded the stock to an 'Equal-Weight' rating with a target price of $28, down from $60. Conversely, RBC Capital maintained an 'Outperform' rating with a target of $48, while Wells Fargo kept its 'Overweight' rating with a target of $75. The consensus remains strong with a recommendation key of 'strong buy' based on a mean target price of $61.46.
What uniQure N.V. Does
uniQure N.V. specializes in developing gene therapies for patients with rare diseases. Its lead product, HEMGENIX, helps individuals with hemophilia B, while other candidates target conditions like Huntington's disease and amyotrophic lateral sclerosis (ALS). The recent insider transactions and analyst ratings highlight the ongoing interest in the company's innovative treatments.
What's Ahead for uniQure N.V.
As we move forward, investors will be watching for uniQure's next earnings report on November 9, 2026. The recent trades by insiders and analyst adjustments will also be monitored closely, as they can influence market perceptions and future trading activity. Remember, the recent insider transactions reflect positions as of the reporting date and may not represent current holdings.
Related Filing Alerts
Source: Matthew Kapusta's Form 4 filing on $QURE (Jun 18, 2026). Find the original filing: QURE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts